ArticleThe World Allergy Organization journal2026
Differential associations of IgG-aFcεRI and IgG-aIgE autoantibodies with clinical phenotypes of type IIb chronic spontaneous urticaria.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic spontaneous urticaria (CSU) is a common mast cell-driven skin disorder characterized by recurrent wheals and/or angioedema lasting more than 6 weeks. A subset of patients shows type IIb autoimmune features, including IgG autoantibodies against FcεRI or IgE, which have been associated with more severe and treatment-refractory disease. Objective: This study aimed to explore the associations of IgG-aFcεRI and IgG-aIgE autoantibodies with clinical and laboratory features of CSU and to assess whether these autoantibody patterns are linked to distinct clinical phenotypes. Methods: Adult patients with CSU underwent standardized clinical evaluation and completed validated patient-reported outcome measures (UCT, UAS7, CU-Q2oL, AECT, AAS, AE-QoL, and VAS). Venous blood samples were collected and analyzed for HSP70, anti-HSP70, and IgG autoantibodies against FcεRI and IgE using ELISA. Additional laboratory data were obtained from the national DataMed system. Statistical analyses were performed using Jamovi v2.7.5, with p < 0.05 considered statistically significant. Results: The study included 205 adults (77.6% female; mean age 42.8 years), of whom 199 were tested for IgG-aFcεRI and IgG-aIgE. Higher IgG-aIgE levels were observed in patients with angioedema (either angioedema alone or urticaria with angioedema), as well as in those reporting accompanying symptoms, receiving omalizumab treatment, living in rural areas, and experiencing predominantly nighttime symptoms. In contrast, higher IgG-aFcεRI levels were associated with wheal-predominant disease and anti-TPO positivity. IgG-aFcεRI levels correlated negatively with IgG-aIgE, neutrophil count, and total IgE, and positively with total IgG. Conclusion: Higher IgG-aIgE levels were associated with angioedema, accompanying symptoms, omalizumab use, rural residence, and nighttime symptom patterns, suggesting an association with distinct clinical features of CSU. In contrast, higher IgG-aFcεRI levels were associated with wheal-predominant disease and anti-TPO positivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.